Occult Cancers Rare in Unprovoked Venous Thromboembolism

Share this content:
Prevalence of occult cancer is low among patients with first unprovoked venous thromboebolism.
Prevalence of occult cancer is low among patients with first unprovoked venous thromboebolism.

Prevalence of occult cancer is low among patients with first unprovoked venous thromboebolism (VTE), according to a Canadian study published in The New England Journal of Medicine.

In a multicenter, open-label, controlled trial, researchers led by Marc Carrier, MD, of the Ottawa Hospital Research Institute randomized 854 patients with unprovoked VTE to either limited occult-cancer screening or limited occult-cancer screening in combination with comprehensive computed tomography (CT).

Primary outcome was confirmed cancer that was missed by the screening strategy but detected by the end of the one-year follow-up.

RELATED: Inferior Vena Cava Filters in Patients with Cancer

The researchers found that 14 of the 431 patients in the limited-screening group as well as 19 of the 423 patients in the limited-screening with CT group had a new diagnosis of occult cancer between randomization and one-year follow-up.

They also found that, upon primary analysis, four occult cancers were missed by the limited-screening strategy as well as five occult cancers in the limited-screening plus CT strategy. No significant difference was found between the two groups with regard to mean time to cancer diagnosis.

Reference

  1. Carrier, Marc, MD, et al. "Screening for Occult Cancer in Unprovoked Venous Thromboembolism." The New England Journal of Medicine. DOI: 10.1056/NEJMoa1506623. June 22, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters